

**For Immediate Release  
Alembic Pharmaceuticals Ltd.  
Consolidated Audited Results for quarter / year ended  
31.03.2013**

**Editors Synopsis**

**Quarter ended 31<sup>st</sup> March 2013**

- **Net Profit after tax up by 115% at Rs. 43.65 crores against Rs. 20.31 crores in corresponding quarter in last year**
- **Profit before tax up by 105% at Rs. 55.18 crores against Rs. 26.94 crores in corresponding quarter in last year**
- **For the quarter net sales up 11% at Rs 378.36 crores against Rs. 342.30 crores in corresponding quarter last year**

**Year ended 31<sup>st</sup> March 2013**

- **Profit after tax up by 27% at Rs. 165.25 crores against Rs. 130.14 crores in last year**
- **Profit before tax up by 28% at Rs. 206.35 crores against Rs. 160.99 crores in last year**
- **EBIDTA margins 16.57% at Rs. 251.96 crores against 14.97% at Rs. 219.43 crores in last year**
- **Net sales grew by 4% for full year at Rs. 1526.00 crores against Rs. 1467.89 crores**

**Vadodara, 2<sup>nd</sup> May 2013**

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 11% increase in revenues to Rs 378.36 crores for the quarter ended 31st March 2013, compared to Rs 342.30 crores in the corresponding quarter last year.

The Company posted an impressive 105% growth in profit before tax at Rs. 55.18 crores for the quarter ended March 2013 against Rs 26.94 crores posted in corresponding quarter last fiscal.

The net profit grew by 115% at Rs. 43.65 crores for the quarter ended March 2013 against Rs. 20.31 crores in corresponding quarter last fiscal.

For full year 2012-13, company posted robust 28% growth in profit before tax of Rs. 206.35 crores against Rs. 160.99 crores for previous year.

The net profit for the year 2012-13 grew by 27% at Rs. 165.25 crores against Rs. 130.14 crores in corresponding quarter last fiscal.

### **Dividend**

The Board has recommended dividend on equity shares at Rs. 2.50 per share i.e. 125 % for 12-13 (P.Y. Re. 1.40 per share i.e. 70%)

### **Domestic Formulation Business**

The domestic formulations posted sales of Rs. 207.52 crores against Rs. 184.47 crores registering healthy 12% growth over the corresponding quarter of the previous year.

Full year numbers were also encouraging since company posted 13% growth in sales at Rs. 886.27 crores against Rs. 782.61 crores in previous year.

As per ORG IMS, Alembic has maintained market share of 1.79%.

Chronic and acute segments grew by 27% and 3% respectively in current year (MAT) versus industry growth rate of 11% and 3% respectively.

The company launched a dermatology division in current year

### **International Generics**

International generics grew by 54% and clocked sales of Rs. 77.66 crores against Rs. 50.37 crores over corresponding quarter last year. On full year basis sales recorded was Rs. 235.77 crores from Rs. 241.80 crores.

During the quarter company launched Desvenlafaxine Base extended release tablets in US. Company also made its new formulations facility partially operational during the quarter.

Cumulative ANDA filings at 57. Cumulative ANDA approvals now stands at 24. Cumulative DMF filings at 60.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in Lacs)

Particulars	Q4FY13	Q4FY12	% Change
<b>Formulation</b>			
Domestic	20,752	18,447	12%
International Branded	1,286	1,774	(-)28%
International Generics	7,766	5,037	54%
<b>API</b>			
Domestic	2,501	1,921	30%
International	5,366	6,814	(-)21%
Export Incentives	165	237	
<b>Total</b>	<b>37,836</b>	<b>34,230</b>	<b>11%</b>

Summary of total revenue (consolidated) for the full year is as under:

(Rs. in Lacs)

Particulars	FY 12-13	FY 11-12	% Change
<b>Formulation</b>			
Domestic	88,627	78,261	13%
International Branded	4,412	5,670	(-)22%
International Generics	23,577	24,180	(-)2%
<b>API</b>			
Domestic	11,382	9,424	21 %
International	23,674	27,922	(-)15%
Export Incentives	928	1,332	
<b>Total</b>	<b>152,600</b>	<b>146,789</b>	<b>4%</b>

The Profit break-up for the quarter:

(Rs. in Lacs)

Particulars	Q4FY13	Q4FY12	% Growth
Operating Income	6558	4084	61%
Profit Before Tax	5518	2694	105%
Net Profit after Tax	4365	2031	115%

The Profit break-up for the full year:

(Rs. in Lacs)

Particulars	FY 12-13	FY 11-12	% Growth
Operating Income	25196	21943	15%
Profit Before Tax	20635	16099	28%
Net Profit after Tax	16525	13014	27%

## **Capital Expenditure**

The Company made its new formulations facility partially operational and and expects completion of project in H1FY14 with enhance capacity of tablets / capsules to 5.0 bn per annum. The company invested Rs. 102 crs in capex in current year of which Rs. 87 crs pertains to new formulation plant.

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3600 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

#### **For more information:**

**Mitanshu Shah**

**Phone: +91 265 – 3007630**

**Email: [mitanshu.shah@alembic.co.in](mailto:mitanshu.shah@alembic.co.in)**

**Alembic Pharmaceuticals Limited**